<DOC>
	<DOCNO>NCT01639456</DOCNO>
	<brief_summary>This phase II trial design test safety efficacy ( disease free survival [ DFS ] ) relate donor HLA-haploidentical NK-cell base therapy treatment acute myelogenous leukemia ( AML ) . The natural killer ( NK ) cell product give patient 60 year old first complete remission 1 2 course standard AML induction . After preparative regimen cyclophosphamide fludarabine , patient receive single infusion either CD3-/CD19- NK cell CD3-/CD56+ NK cell follow short course Interleukin-2 ( IL-2 ) facilitate NK cell survival expansion .</brief_summary>
	<brief_title>CD3/CD19 Depleted CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment Older AML First Complete Remission</brief_title>
	<detailed_description>The trial use single-stage design take place two part . The first part support selection well NK cell product measure vivo NK cell expansion . Successful vivo NK cell expansion define 40 % donor DNA 40 % lymphocytes NK cell day 7 post infusion OR 20 % donor DNA 20 % lymphocytes NK cell day 14 post infusion . Part 1 : 1:1 randomization 10 patient per cohort either : 1 . CD3-/CD19- NK cell product 2 . CD3-/CD56+ purified NK cell product The product well NK cell expansion use rest trial . If result safety profile equivalent , CD56+ selection approach use . If neither approach result successful NK cell expansion , trial stop platform redesign . Part 2 : complete trial enrol additional 26 patient use product deem successful part 1 estimate primary endpoint ( DFS 12 month )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis acute myelogenous leukemia ( except acute promyelocytic leukemia ) first complete remission ( CR1 ) meet follow criterion : Meets definition complete remission morphologic criteria include &lt; 5 % blast moderately cellular ( &gt; 20 % cellularity ) cellular marrow . Complete remission ( CR ) achieve 2 cycle standard induction chemotherapy . Early reinduction therapy base residual disease day 14 bone marrow ( BM ) count 2nd cycle . Prior therapy demethylating agent ( i.e . azacitidine ) allow , patient must attain CR standard cytotoxic therapy ( define absolute neutrophil count ( ANC ) &gt; 1000 cells/μL , platelet &gt; 100 x 10^9/L ) No 3 month lapse attainment CR1 No acute myelogenous leukemia ( AML ) consolidation therapy administer prior enrollment Not candidate allogeneic stem cell transplantation ≥ 60 year age Karnofsky performance status ≥ 70 % Available related HLA haploidentical natural killer ( NK ) cell donor ( sibling , offspring , offspring HLA identical sibling ) least Class I serologic type A &amp; B locus ( donor age 1875 year ) At least 30 day since last dose chemotherapy Adequate organ function within 14 day enrollment define : Creatinine : ≤ 2.0 mg/dL Hepatic : aspartate aminotransferase ( SGOT ) alanine aminotransferase ( SGPT ) &lt; 5 x upper limit institutional normal ( ULN ) Pulmonary : oxygen saturation ≥ 90 % room air Cardiac : leave ventricular ejection fraction ( LVEF ) echocardiogram ( ECHO MUGA ) ≥ 40 % , uncontrolled angina , uncontrolled atrial ventricular arrhythmia , evidence acute ischemia active conduction system abnormality ( rate control afib exclusion ) Ability prednisone immunosuppressive drug least 3 day prior NK cell infusion ( exclude preparative regimen premeds ) Voluntary write consent Biphenotypic acute leukemia New progressive pulmonary infiltrates screen chest xray chest Computed Tomography scan evaluate bronchoscopy ( feasible ) . Infiltrates attributed infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 4 week presume documented fungal infection ) . Uncontrolled bacterial , fungal , viral infection include human immunodeficiency virus ( HIV ) chronic asymptomatic viral hepatitis allow Pleural effusion large enough detectable chest xray Known hypersensitivity one study agent Donor Selection : Related donor ( sibling , offspring , offspring HLA identical sibling ) 1875 year age At least 40 kilogram In general good health determine medical provider Negative hepatitis HIV donor viral screen HLAhaploidentical donor/recipient match least Class I serologic type A &amp; B locus Not pregnant Voluntary write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
</DOC>